医学
多发性骨髓瘤
耐火材料(行星科学)
重症监护医学
肿瘤科
不利影响
乐观 主义
内科学
心理学
社会心理学
天体生物学
物理
作者
Deevyashali Parekh,Yun Kyoung Ryu,Kevin Tony Jamouss,Justin Hassani,Maroun Bou Zerdan,Shahzad Raza
出处
期刊:Cancers
[MDPI AG]
日期:2024-08-23
卷期号:16 (17): 2931-2931
标识
DOI:10.3390/cancers16172931
摘要
Multiple myeloma is a heterogeneous condition characterized by the proliferation of monoclonal B-cells, for which there is currently no curative treatment available. Relapses are, unfortunately, common after first-line treatment. While the prognosis for relapsed refractory multiple myeloma is generally poor, advances in the treatment of relapsed or refractory multiple myeloma offer hope. However, the expansion of effective options in targeted treatment offers renewed optimism and hope that patients who fail on older therapies may respond to newer modalities, which are often used in combination. We review currently approved and novel investigational agents classified by mechanisms of action, efficacy, approved setting, and adverse events. We delve into future directions of treatment for relapsed/refractory multiple myeloma, reviewing novel agents and therapeutic targets for the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI